ASH 2016 - Multiple Myeloma

Leslie Lauersdorf insist that it's vital to inform your patients about what's involved in beginning daratumumab treatments, especially because of the lengthy chair time.

In a subgroup analysis of the POLLUX trial, daratumumab plus lenalidomide/dexamethasone was associated with superior progression-free survival and response rates versus lenalidomide/dexamethasone alone among patients who were previously treated with bortezomib or who were bortezomib-refractory or lenalidomide-naïve.

Clinical outcomes were better when daratumumab was added to a regimen of patients with relapsed/refractory multiple myeloma who received prior therapy.
Recent data indicate that daratumumab can further decrease minimal residual disease burden when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.
Beth Faiman identifies how the Janssen CarePath program can financially help anyone who is diagnosed with multiple myeloma and requires daratumumab.
Leslie Lauersdorf notes that having patients assist in managing their own side effects is important to help them stay on treatment and improve their quality of life.
Tiffany Richards insists on the importance of survivorship care in patients with multiple myeloma and explains how to make sure patients stay as healthy as possible for as long as possible.
Tiffany Richards is excited about all the new multiple myeloma treatments that are being introduced, but understands that the question of how to best utilize these drugs still remains to be answered.
Leslie Lauersdorf addresses the challenges associated with staying abreast of the side effects, management, and sequencing for new multiple myeloma treatments.
Tiffany Richards identifies the many recources she leverages to stay current on new treatments.
Page 2 of 6
Results 11 - 20 of 51